Plain-English translation of NCT06162884 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers are testing whether a new artificial intelligence tool can predict which patients with pulmonary fibrosis (lung scarring) will get worse quickly. The study collects information from lung scans, breathing tests, and walking tests to see if this AI tool can accurately spot patients who need anti-fibrotic treatment earlier—before their disease progresses significantly.
Right now, doctors can only tell if pulmonary fibrosis is getting worse after changes have already happened. This study aims to catch progression earlier using AI, so patients can start treatment before their lungs decline further.
You likely qualify if…
You likely don't qualify if…
You will visit the UCLA ILD Center for a baseline appointment where you'll have a high-resolution CT scan of your lungs, perform breathing tests (spirometry and diffusion capacity tests), walk for 6 minutes while your oxygen levels are monitored, and answer questions about your symptoms. The study will then track you over time—you'll be grouped based on your scan results—and researchers will follow your progress using your routine medical visits and test results, without adding any new medications or treatments to your regular care.
AI-generated summary from trial data · Jun 11, 2026 · Not medical advice
United States
Sponsor
University of California, Los Angeles
Collaborators
Boehringer Ingelheim
Enrollment target
~200 participants
Started
November 2024
Primary completion
November 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in June 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Grace Hyun Kim, PhD
UCLA Division of Pulmonary, Critical Care, and Hospitals
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.